Skip to Content

Xultophy 100/3.6 Dosage

Generic name: INSULIN DEGLUDEC 100[iU] in 1mL, LIRAGLUTIDE 3.6mg in 1mL
Dosage form: injection, solution

Medically reviewed by Drugs.com. Last updated on Nov 15, 2019.

Important Dosage Information

XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide.
Administer XULTOPHY 100/3.6 by subcutaneous injection once-daily at the same time each day with or without food.
The XULTOPHY 100/3.6 pen delivers doses from 10 to 50 units with each injection. Table 1 presents the units of insulin degludec and the milligrams of liraglutide in each dosage of XULTOPHY 100/3.6 [see Dosage and Administration (2.2)].
The maximum dose of XULTOPHY 100/3.6 is 50 units daily (50 units of insulin degludec and 1.8 mg of liraglutide) [see Warnings and Precautions (5.5)].

Recommended Starting Dose

In patients naïve to basal insulin or a GLP-1 receptor agonist

The recommended starting dose of XULTOPHY 100/3.6 is 10 units (10 units of insulin degludec and 0.36 mg of liraglutide) given subcutaneously once-daily (see Table 1).

In patients currently on basal insulin or a GLP-1 receptor agonist

Discontinue therapy with basal insulin or GLP-1 receptor agonist prior to initiation of XULTOPHY 100/3.6.
The recommended starting dose of XULTOPHY 100/3.6 is 16 units (16 units of insulin degludec and 0.58 mg of liraglutide) given subcutaneously once-daily (see Table 1).

Table 1: Units of Insulin Degludec and Milligrams of Liraglutide in Each Dosage of XULTOPHY 100/3.6

XULTOPHY 100/3.6

(dose counter display)*

insulin degludec

component dose

liraglutide

component dose

Comment

▪▪ ─

---

---

Priming symbol

10

10 units

0.36 mg

Recommended starting dose for patients naïve to basal insulin or GLP-1 receptor agonist

11

11 units

0.4 mg

12

12 units

0.43 mg

13

13 units

0.47 mg

14

14 units

0.5 mg

15

15 units

0.54 mg

16

16 units

0.58 mg

Recommended starting dose for patients currently on basal insulin or GLP-1 receptor agonist

17

17 units

0.61 mg

18

18 units

0.65 mg

19

19 units

0.68 mg

20

20 units

0.72 mg

21

21 units

0.76 mg

22

22 units

0.79 mg

23

23 units

0.83 mg

24

24 units

0.86 mg

25

25 units

0.9 mg

26

26 units

0.94 mg

27

27 units

0.97 mg

28

28 units

1.01 mg

29

29 units

1.04 mg

30

30 units

1.08 mg

31

31 units

1.12 mg

32

32 units

1.15 mg

33

33 units

1.19 mg

34

34 units

1.22 mg

35

35 units

1.26 mg

36

36 units

1.3 mg

37

37 units

1.33 mg

38

38 units

1.37 mg

39

39 units

1.4 mg

40

40 units

1.44 mg

41

41 units

1.48 mg

42

42 units

1.51 mg

43

43 units

1.55 mg

44

44 units

1.58 mg

45

45 units

1.62 mg

46

46 units

1.66 mg

47

47 units

1.69 mg

48

48 units

1.73 mg

49

49 units

1.76 mg

50

50 units

1.8 mg

Maximum daily dosage [see Warnings and Precautions (5.5)]

* The dose counter on the XULTOPHY 100/3.6 pen displays numbers for the even units and displays lines for the odd units.

Titration of XULTOPHY 100/3.6

After starting the recommended starting dose of XULTOPHY 100/3.6 [see Dosage and Administration (2.2)], titrate the dosage upwards or downwards by two units (see Table 2) once weekly or twice weekly (every three to four days), based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal until the desired fasting plasma glucose is achieved.
To minimize the risk of hypoglycemia or hyperglycemia, additional titration may be needed with changes in physical activity, meal patterns (i.e., macronutrient content or timing of food intake), or renal or hepatic function; during acute illness; or when used with other medications [see Warnings and Precautions (5.4) and Drug Interactions (7)].

Table 2: Recommended Titration of XULTOPHY 100/3.6 (Once or Twice Weekly)

Self-Monitored Fasting Plasma Glucose

XULTOPHY 100/3.6 Dosage Adjustment

Above target range

+ 2 units (2 units of insulin degludec and 0.072 mg of liraglutide)

Within target range

0 units

Below target range

- 2 units (2 units of insulin degludec and 0.072 mg of liraglutide)

Missed Doses

Instruct patients who miss a dose of XULTOPHY 100/3.6 to resume the once-daily regimen as prescribed with the next scheduled dose. Do not administer an extra dose or increase the dose to make up for the missed dose.
If more than three days have elapsed since the last XULTOPHY 100/3.6 dose, reinitiate XULTOPHY 100/3.6 at the recommended starting dose to mitigate any gastrointestinal symptoms associated with reinitiation of treatment [see Dosage and Administration (2.1, 2.2, 2.3)].

Important Administration Instructions

The XULTOPHY 100/3.6 pen is for single-patient-use only [see Warnings and Precautions (5.3)].
Train patients on proper use and injection technique before initiating XULTOPHY 100/3.6.
Always check the label on the XULTOPHY 100/3.6 pen before administration [see Warnings and Precautions (5.5)].
Inspect visually for particulate matter and discoloration prior to administration. Only use XULTOPHY 100/3.6 if the solution appears clear and colorless.
Inject XULTOPHY 100/3.6 subcutaneously into the thigh, upper arm, or abdomen.
Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneousamyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (5.4), Adverse Reactions (6.1, 6.3)].
During changes to a patient’s insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions (5.4)].
Use XULTOPHY 100/3.6 with caution in patients with visual impairment who may rely on audible clicks to dial their dose.
The XULTOPHY 100/3.6 pen dials in one-unit increments.
Do not administer XULTOPHY 100/3.6 intravenously, intramuscularly, or in an insulin infusion pump.
Do not dilute or mix XULTOPHY 100/3.6 with any other insulin products or solutions.
Do not split the dose of XULTOPHY 100/3.6.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions

More about Xultophy (insulin degludec / liraglutide)

Consumer resources

Professional resources

Related treatment guides

Hide